The State of Weight-Loss Drugs

The State of Weight-Loss Drugs

$150 billion. That’s how much some experts estimate weight-loss drugs could bring in in sales within the next five years. Motley Fool analyst Karl Thiel joins Ricky Mulvey to check in on the GLP-1 landscape. They also discuss: - How weight-loss drugs actually work, and how big-name prescriptions differ from each other. - What investors need to know about Ozempic and Mounjarno’s patent cliffs. - The scenarios in which Novo Nordisk and Eli Lilly are actually undervalued. Companies discussed: LLY, NOVO, HIMS, PFE, RHHBY, VKTX, GPCR, ISRG Host: Ricky Mulvey Guest: Karl Thiel Producer: Mary Long Engineer: Rick Engdahl Learn more about your ad choices. Visit megaphone.fm/adchoices

Episoder(2050)

Populært innen Business og økonomi

stopp-verden
rss-penger-polser-og-politikk
e24-podden
dine-penger-pengeradet
rss-borsmorgen-okonominyhetene
lydartikler-fra-aftenposten
rss-vass-knepp-show
finansredaksjonen
tid-er-penger-en-podcast-med-peter-warren
pengepodden-2
stormkast-med-valebrokk-stordalen
livet-pa-veien-med-jan-erik-larssen
morgenkaffen-med-finansavisen
utbytte
rss-markedspuls-2
lederpodden
okonomiamatorene
rss-sunn-okonomi
rss-impressions-2
rss-investering-gjort-enkelt